Subscribe To
Pfizer and biontech launch clinical study of covid vaccine targeting omicron
Pfizer CEO Albert Bourla has said the company will have the omicron vaccine ready by March....
January 25, 2022, 6:45 am
Arovella therapeutics appoints senior preclinical development and translational medicine expert to strengthen team
Arovella Therapeutics Ltd (ASX:ALA) has welcomed Dr Mini Bharathan to the executive team to lead preclinical trials of the newly acquired DKK1 peptide...
January 24, 2022, 8:25 pm
Arovella therapeutics appoints senior preclinical development and translational medicine expert to strengthen team
Arovella Therapeutics Ltd (ASX:ALA) has welcomed Dr Mini Bharathan to the executive team to lead preclinical trials of the newly acquired DKK1 peptide...
January 24, 2022, 8:25 pm
Arovella therapeutics appoints senior preclinical development and translational medicine expert to strengthen team
Arovella Therapeutics Ltd (ASX:ALA) has welcomed Dr Mini Bharathan to the executive team to lead preclinical trials of the newly acquired DKK1 peptide...
January 24, 2022, 8:25 pm
Aim immunotech announces positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian canc...
January 24, 2022, 9:48 am
Aim immunotech announces positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian canc...
January 24, 2022, 9:48 am
Aim immunotech announces positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian canc...
January 24, 2022, 9:48 am
Arcturus therapeutics' covid-19 booster clinical trial show encouraging neutralizing antibody responses
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational,...
January 24, 2022, 9:23 am
Arcturus therapeutics' covid-19 booster clinical trial show encouraging neutralizing antibody responses
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational,...
January 24, 2022, 9:23 am
Arcturus therapeutics' covid-19 booster clinical trial show encouraging neutralizing antibody responses
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational,...
January 24, 2022, 9:23 am
Kaleido biosciences to present updated data of kb295 in ulcerative colitis at the 2022 crohn's and colitis congress
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, ...
January 21, 2022, 11:04 am
Kaleido biosciences to present updated data of kb295 in ulcerative colitis at the 2022 crohn's and colitis congress
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, ...
January 21, 2022, 11:04 am
Kaleido biosciences to present updated data of kb295 in ulcerative colitis at the 2022 crohn's and colitis congress
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, ...
January 21, 2022, 11:04 am
Aslan pharma kickstarts mid-stage atopic dermatitis trial, data expected in 2023
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with...
January 21, 2022, 6:36 am
Aslan pharma kickstarts mid-stage atopic dermatitis trial, data expected in 2023
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with...
January 21, 2022, 6:36 am
Aslan pharma kickstarts mid-stage atopic dermatitis trial, data expected in 2023
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with...
January 21, 2022, 6:36 am
Senate panel approves antitrust bill targeting apple, google and amazon
The Senate Judiciary Committee on Thursday overwhelmingly passed antitrust legislation barring tech's biggest platforms from favoring their products a...
January 20, 2022, 2:08 pm
Senate panel approves antitrust bill targeting apple, google and amazon
The Senate Judiciary Committee on Thursday overwhelmingly passed antitrust legislation barring tech's biggest platforms from favoring their products a...
January 20, 2022, 2:08 pm
Senate panel approves antitrust bill targeting apple, google and amazon
The Senate Judiciary Committee on Thursday overwhelmingly passed antitrust legislation barring tech's biggest platforms from favoring their products a...
January 20, 2022, 2:08 pm
Big tech's chorus of critics grows ahead of hill hearing
Thursday (Jan. 20) looms as an important day in the annals of legislation targeting and likely reshapin...
January 20, 2022, 11:06 am